Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials

Table 3 Preoperative CRT versus preoperative CT

Study and year	Sample size	Treatment approach	Treatment schedule	3 y or 5 y OS (CRT V. CT + S)
Stahl, [33]	119	CRT-Surgery V. CT-Surgery	Scheme of CRT: GTV30Gy/15f cisplatin (50 mg/m2), etoposide (80 mg/m2)	3y: 52% V. 49%
Stahl, [33]	119	CRT-Surgery V. CT-Surgery	Scheme of CT: 5-Fu (2 g/m2) leucovorin (500 mg/m2) cisplatin (50 mg/m2)	5y: 45% V. 36%
Burmeister, [32]	75	CRT-Surgery V. CT-Surgery	Scheme of CRT: Cisplatin (80 mg/m2) 5-Fu (1000 mg/m2/d) GTV35Gy/15f	3y: 47.4% V. 27.7%
				5y: NM
			Scheme of CT: Cisplatin(80 mg/m2) 5-Fu (1000 mg/m2/d)	5y: NM

Note: OS: overall survival; CRT: preoperative chemoradiation therapy; CT: preoperative chemotherapy; V: versus; Surg: surgery; 5-Fu: fluorouracil; NM: not mentioned.

ISSN: 1471-2407